Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 570 clinical trials
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide (SPd)

electrophoresis
daratumumab
monoclonal antibodies
immunomodulatory imide drug
ixazomib
  • 57 views
  • 24 Jan, 2022
  • 18 locations
4SCAR-CD44v6 T Cell Therapy Targeting Cancer

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

  • 10 views
  • 25 Jan, 2021
  • 4 locations
Daratumumab and Belatacept for Desensitization

Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found for …

  • 0 views
  • 02 Dec, 2021
  • 1 location
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

ASCT during initial treatment (Cohort 2c) Approximately 181 subjects will be enrolled into one of two cohorts. Cohort 1 will enroll approximately 73 RRMM subjects with 3 prior anti-myeloma treatment

electrophoresis
maintenance therapy
serum proteins
refractory multiple myeloma
cell transplantation
  • 12 views
  • 09 Sep, 2021
  • 27 locations
RAdiotherapy for Metastatic Spinal Cord Compression With Increased Radiation dosES

This clinical study aims to investigate whether high-precision radiotherapy, as supposed, leads to a better control of the irradiated spinal cord metastases when compared to conventional radiotherapy. This means that a progression or recurrence of motor deficits (weakness) of the legs following radiotherapy can be avoided more effectively. Furthermore, the …

  • 0 views
  • 11 May, 2021
  • 2 locations
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

lenalidomide
rituximab
tumor burden
platelet count
bendamustine
  • 47 views
  • 06 Sep, 2021
  • 37 locations
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide

neutrophil count
cell transplantation
dexamethasone
lenalidomide
measurable disease
  • 14 views
  • 30 Jul, 2021
  • 38 locations
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.

refractory multiple myeloma
  • 23 views
  • 17 Oct, 2021
  • 17 locations
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).

lenalidomide
measurable disease
pomalidomide
dexamethasone
refractory multiple myeloma
  • 2 views
  • 26 Jul, 2021
  • 74 locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085

daratumumab
monoclonal antibodies
ixazomib
monoclonal protein
line of therapy
  • 30 views
  • 21 Jan, 2022
  • 22 locations